PAD: Medtronic's In.Pact Admiral drug-eluting balloon bests Bard's Lutonix at 6 months

Results from a clinical trial of Medtronic's In.Pact Admiral drug-eluting balloon for peripheral artery disease show lower target lesion revascularization rates than rival C.R. Bard's Lutonix DEB.

C.R. Bard, Medtronic

News Well, Clinical Trials, Peripheral Artery Disease

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1hlg4qS